Cancer genome sequencing has identified high-frequency mutations of splicing factor SF3B1 in hematologic malignancies such as myelodysplastic syndrome and chronic lymphocytic leukemia (CLL) (1–3). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.